Objective: To analyze the mediating effect of social support between family resilience and quality of life among elderly patients with Alzheimer's disease (AD), so as to provide the basis for improving the quality of life among elderly patients with AD. Methods: Elderly patients with AD who aged >60 years admitted to Wenzhou Seventh People's Hospital from August 2017 to June 2021 were selected. Data on demographic information, the severity of AD, and the profile of the primary caregivers were collected through questionnaire surveys. Social support, family resilience, and quality of life were assessed using the Social Support Rating Scale, the Shortened Chinese Version of the Family Resilience Assessment Scale, and the Chinese Version of the Quality of Life in Alzheimer's Disease Scale, respectively. The Process macro program was used to analyze the mediating effect of social support between family resilience and quality of life. Results: A total of 137 elderly patients with AD were surveyed. The mean age of the participants was (69.26±10.93) years. Among them, there were 63 males (45.99%) and 74 females (54.01%). The mean scores for social support, family resilience, and quality of life were (27.93±4.28), (97.34±10.06), and (27.82±7.27) points, respectively. The results of the mediating effect analysis indicated that family resilience could directly and positively affect the quality of life, with an effect value of 0.319 (95%CI: 0.122-0.491). It could also indirectly and positively affect the quality of life through social support, with an effect value of 0.118 (95%CI: 0.030-0.248). The mediating effect accounted for 26.42% of the total effect. Conclusion Social support plays a positive mediating role between family resilience and quality of life among elderly patients with AD.

Colorectal cancer (CRC) is a prevalent malignant tumor often leading to liver metastasis and mortality. Despite some success with PD-1/PD-L1 immunotherapy, the response rate for colon cancer patients remains relatively low. This is closely related to the immunosuppressive tumor microenvironment mediated by tumor-associated macrophages (TAMs). Our previous work identified that a phosphoglycerate mutase 1 (PGAM1) allosteric inhibitor, HKB99, exerts a range of anti-tumor activities in lung cancer. Here, we found that upregulation of PGAM1 correlates with increased levels of M2-like tumor-associated macrophages (TAMs) in human colon cancer samples, particularly in liver metastatic tissues. HKB99 suppressed tumor growth and metastasis in cell culture and syngeneic tumor models. M2-polarization, induced by colon cancer cell co-culture, was reversed by HKB99. Conversely, the increased migration of colon cancer cells by M2-TAMs was remarkably restrained by HKB99. Notably, a decrease in TAM infiltration was required for the HKB99-mediated anti-tumor effect, along with an increase in CD8⁺ T cell infiltration. Moreover, HKB99 improved the efficacy of anti-PD-1 treatment in syngeneic tumors. Overall, this study highlights HKB99's inhibitory activity in TAM-mediated colon cancer progression. Targeting PGAM1 could lead to novel therapeutic strategies and enhance the effectiveness of existing immunotherapies for colon cancer.

Neoadjuvant chemotherapy has become an indispensable weapon against high-risk resectable cancers, which benefits from tumor downstaging. However, the utility of chemotherapeutics alone as a neoadjuvant agent is incapable of generating durable therapeutic benefits to prevent postsurgical tumor metastasis and recurrence. Herein, a tactical nanomissile (TALE), equipped with a guidance system (PD-L1 monoclonal antibody), ammunition (mitoxantrone, Mit), and projectile bodies (tertiary amines modified azobenzene derivatives), is designed as a neoadjuvant chemo-immunotherapy setting, which aims at targeting tumor cells, and fast-releasing Mit owing to the intracellular azoreductase, thereby inducing immunogenic tumor cells death, and forming an in situ tumor vaccine containing damage-associated molecular patterns and multiple tumor antigen epitopes to mobilize the immune system. The formed in situ tumor vaccine can recruit and activate antigen-presenting cells, and ultimately increase the infiltration of CD8⁺ T cells while reversing the immunosuppression microenvironment. Moreover, this approach provokes a robust systemic immune response and immunological memory, as evidenced by preventing 83.3% of mice from postsurgical metastasis or recurrence in the B16-F10 tumor mouse model. Collectively, our results highlight the potential of TALE as a neoadjuvant chemo-immunotherapy paradigm that can not only debulk tumors but generate a long-term immunosurveillance to maximize the durable benefits of neoadjuvant chemotherapy.